Limitations With Standard of Care in ICI-Pretreated Patients With NSCLC
Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.
Karen L. Reckamp, MD, director, Medical Oncology, associate director, Clinical Research, and Medical Oncology director, Lung Institute at Samuel Oschin Cancer Center, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer (NSCLC).
In the phase 2 Lung-MAP substudy S1800A (NCT03971474), the combination of pembrolizumab (Keytruda) and ramucirumab (Cyramza) was evaluated in patients with stage IV, previously-treated advanced NSCLC who acquired resistance to immune checkpoint inhibitors (ICI). Acquired resistance in the study was defined as previous ICI therapy for at least 84 days with progressive disease on or after therapy.
Reckamp also provides an overview on what makes the combination of ramucirumab and pembrolizumab a promising option for this patient population.
Transcription:
0:08 | The limitations of standard of care are really that the combination of ramucirumab and docetaxel was approved in about 2014. This has been the only standard in addition to single-agent chemotherapy for patients who have had tumor growth on chemotherapy and immune checkpoint inhibitor therapy.
0:31 | We really are at a point where we need some novel therapies, novel combinations, and uniquely ramucirumab/pembrolizumab is a non-chemotherapy option for patients. That's 1 way that makes this combination exciting.
